Premium
P7C3‐A20 alleviates fatty liver by shaping gut microbiota and inducing FGF21/FGF1, via the AMP‐activated protein kinase/CREB regulated transcription coactivator 2 pathway
Author(s) -
Hua Xia,
Sun DiYang,
Zhang WenJie,
Fu JiangTao,
Tong Jie,
Sun SiJia,
Zeng FeiYan,
Ouyang ShenXi,
Zhang GuoYan,
Wang ShuNa,
Li DongJie,
Miao ChaoYu,
Wang Pei
Publication year - 2021
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.15008
Subject(s) - amp activated protein kinase , endocrinology , medicine , ampk , biology , fgf21 , fatty liver , protein kinase a , microbiology and biotechnology , biochemistry , kinase , fibroblast growth factor , receptor , disease
Non-alcoholic fatty liver disease (NAFLD) is a worldwide public health problem with no established pharmacological therapy. Here, we explored the potential benefit of P7C3-A20, a novel aminopropyl carbazole compound with neuroprotective activity, in a NAFLD model, induced in mice by a high-fat diet (HFD).